Navigation Links
Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
Date:3/12/2009

Gallios(TM) Flow Cytometry System Offers New Standard of Performance for Researchers

ORANGE COUNTY, Calif., March 12 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, and manufacturer of products that simplify and automate complex biomedical testing, announced today that it has launched the Gallios Flow Cytometer, the first of several instrument, software and reagent introductions in the year for both clinical and research applications in flow cytometry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

The new Gallios Flow Cytometer, targeted to the research market, delivers analytical excellence combined with high speed data collection. Features - including advanced optics, patented electronics design, and novel software tools - improve lab workflow and quality control, delivering increased sensitivity and resolution in less time and at higher speeds. Researchers can readily see small and subtle changes in cell populations, and the system accelerates data generation.

"Every aspect of the Gallios design increases application performance. When combined with our broad and high quality reagent portfolio, we provide a new and powerful solution for cellular analysis, increasing productivity and improving the reliability and reproducibility of results," said Cynthia Collins, group vice president of Cellular Analysis at Beckman Coulter.

The analyzer's efficient, compact design allows laboratories to maximize valuable space. The system comes in three scaleable configurations that allow for future addition of more lasers and fluorescence detectors as the need for complex multi-color flow cytometry expands.

Collins added, "We are adding a number of exciting products to our flow cytometry portfolio this year. They are a testament to our commitment to enhancing the efficiency of flow cytometry laboratories around the globe."

About Beckman Coulter

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.

    Contacts:  Mary Luthy, Beckman Coulter   Cynthia Skoglund, Beckman Coulter
               Corporate Communications      Investor Relations
               (714) 773-7964                (714) 773-7620


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Beckman Coulter to Present at Upcoming Healthcare Conferences
2. Beckman Coulter Announces Third Quarter 2008 Results
3. Beckman Coulter to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens
5. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
6. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
7. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
8. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
9. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
10. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
11. Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... The ... care facility – Avamere Transitional Care of Puget Sound ; located at ... health care center will provide patients recovering from illness or injury with intensive ...
(Date:12/5/2016)... VA (PRWEB) , ... December 05, 2016 , ... ... today announced it has been featured in SuperbCrew magazine, a leading online tech ... tech world. This interview, now featured on SuperbCrew.com, explores the state of enterprise ...
(Date:12/5/2016)... ... ... Researchers at Johns Hopkins All Children’s Hospital want to learn more about ... of three years, researchers will study concussions and changes in brain function by monitoring ... sensors, will track the location and force of the hit. The sensors store data ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy ... through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the ... 26 people will be diagnosed with epilepsy within their lifetime. With such a ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Sanovas, Inc., a life science asset holding ... its wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed ... - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed ...
(Date:12/5/2016)... 2016  CVS Health, the nation,s largest pharmacy innovation ... score of 100 percent on the Corporate Equality Index ... an annual national benchmarking survey and report on corporate ... the Human Rights Campaign Foundation. "Our ... colleagues, customers and suppliers bring to CVS Health," said ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 /PRNewswire/ ... announced preliminary safety and efficacy data from a ... selective MDM2 inhibitor, suggesting that DS-3032 may be ... acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome ... of the phase 1 study of DS-3032 were presented ...
Breaking Medicine Technology: